Today, Intercept Pharmaceuticals Inc. (ICPT) Stock Rating Reaffirm by Robert W. Baird

Today, Intercept Pharmaceuticals Inc. (ICPT) Stock Rating Reaffirm by Robert W. Baird

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reiterated by research analysts at Robert W. Baird in a research report issued on Monday. They currently have a $332.00 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s target price indicates a potential upside of 186.60% from the stock’s previous close.

ICPT has been the topic of several other reports. Morgan Stanley reissued a “sell” rating and set a $80.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $147.00 price target on the stock in a research report on Wednesday, October 26th. Wedbush reissued an “outperform” rating and set a $239.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, September 16th. Credit Suisse Group AG reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, September 22nd. Finally, Laidlaw cut shares of Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and cut their price target for the stock from $345.00 to $105.00 in a research report on Friday, August 5th. Five investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and an average target price of $177.07.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.37% during midday trading on Monday, reaching $115.84. The company had a trading volume of 207,545 shares. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $186.87. The stock’s 50 day moving average price is $124.14 and its 200-day moving average price is $145.79. The firm’s market capitalization is $2.87 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.82) by $0.23. The firm earned $4.70 million during the quarter, compared to analyst estimates of $4.77 million. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The company’s revenue for the quarter was up 1051.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.10) EPS. On average, equities research analysts anticipate that Intercept Pharmaceuticals will post ($15.63) earnings per share for the current year.

In related news, CMO David Shapiro sold 1,513 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $163.08, for a total transaction of $246,740.04. Following the sale, the chief marketing officer now owns 46,196 shares in the company, valued at approximately $7,533,643.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mark Pruzanski sold 35,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $165.00, for a total transaction of $5,775,000.00. Following the sale, the chief executive officer now owns 579,314 shares in the company, valued at approximately $95,586,810. The disclosure for this sale can be found here. Corporate insiders own 9.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. CENTRAL TRUST Co purchased a new stake in Intercept Pharmaceuticals during the second quarter valued at about $107,000. The Manufacturers Life Insurance Company bought a new stake in shares of Intercept Pharmaceuticals during the third quarter worth $114,000. KBC Group NV raised its stake in shares of Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 779 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 67.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 915 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 370 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 52 shares in the last quarter. Institutional investors and hedge funds own 81.54% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Related posts

Leave a Comment